Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FDA approved several label changes for the statin class of cholesterol drugs, including eliminating the need for routine periodic monitoring
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury